Foghorn Therapeutics (FHTX) Depreciation & Amortization (CF) (2019 - 2026)

Foghorn Therapeutics' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $200000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 75.82% year-over-year to $200000.0 in Q1 2026; TTM through Mar 2026 was $2.8 million, a 7.69% decrease from a year earlier, with the FY2025 full-year figure at $3.3 million, up 7.48% from the prior year.
• Depreciation & Amortization (CF) fell to $200000.0 in Q1 2026 per FHTX's latest filing, from $832000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $900000.0 in Q3 2022 and bottomed at $200000.0 in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $827000.0 (2022), against an average of $793294.1.
• Across the five-year window, Depreciation & Amortization (CF) rose 28.57% in 2025 and plunged 75.82% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $827000.0 in 2022, then rose by 8.83% to $900000.0 in 2023, then slipped by 17.67% to $741000.0 in 2024, then advanced by 12.28% to $832000.0 in 2025, then plunged by 75.96% to $200000.0 in 2026.
• Per Business Quant, the three latest FHTX Depreciation & Amortization (CF) figures stand at $200000.0 (Q1 2026), $832000.0 (Q4 2025), and $900000.0 (Q3 2025).